Vés al contingut

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Obert
  • Codi protocol: BGB-3111-306
  • Codi EudraCT: 2019-000413-36
  • Grup de recerca: Immunologia Translacional
  • Servei: Pediatria General i Especialitats
  • Investigador/a principal:  Marín Sánchez, Ana María
  • Fase: Fase III
  • Estat reclutament: Reclutant voluntaris